CASE REPORT article
Front. Pharmacol.
Sec. Neuropharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1598971
Synergistic Central Nervous System Depression of Baclofen and Pregabalin: Clinical Pharmacist-Driven Case Analysis and Case Review
Provisionally accepted
- 1Capital Medical University, Beijing, China
- 2Department of Pharmacy,Beijing Jishuitan Hospital, Capital Medical University, Beijing, China
- 3Department of Spine Surgery, Beijing Jishuitan Hospital, Beijing, Beijing Municipality, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Baclofen, a γ-aminobutyric acid (GABA) derivative, and Pregabalin, a GABA analogue, are widely prescribed for muscle spasm and neuropathic pain. This first-reported case demonstrates synergistic central nervous system (CNS) depression of Baclofen (30 mg/day) and Pregabalin (300 mg/day) in a patient with mild renal impairment [estimated glomerular filtration rate, (eGFR)=77.26 mL/min].Case Presentation: A 68-year-old female with renal impairment developed progressive CNS depression (somnolence, coma) following combined Baclofen (30 mg/day) and Pregabalin (300 mg/day) therapy after spinal fusion surgery. CNS depression was completely resolved 48 hours after drug discontinuation.Pregabalin in renal impairment. Dose adjustments based on creatinine clearance (CLcr) are strongly recommended. Particular attention should be given to initiating therapy with reduced starting doses in patients at elevated risk of CNS depression.
Keywords: Baclofen, pregabalin, Drug-induced CNS depression, renal impairment, Synergistic toxicity
Received: 24 Mar 2025; Accepted: 22 May 2025.
Copyright: © 2025 XIE, Wu, JIN, MAO, ZHEN and ZHANG. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Wei ZHANG, Department of Pharmacy,Beijing Jishuitan Hospital, Capital Medical University, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.